Hyundai Cancer Institute
Recurrent and Refractory Cancer Treatment Program
The Recurrent and Refractory Cancer (RRC) Treatment Program is dedicated to working with patients whose cancers have recurred or are not responding to treatments. Our team specialists work with the Children’s Oncology Group (COG) and other experts to offer patients Phase I clinical trials and innovative treatment protocols. Each treatment is customized to meet the specific needs of the individual patient based on the type and stage of their cancer. All new patients are seen within 48 hours of being referred by their physician.
The RRC team treats all recurrent and refractory cancers. Recurrent cancers are those that have returned after a patient has been told his or her cancer is in remission. The team also treats refractory cancers, which are cancers that do not respond to treatment or stop responding during the course of treatment.
Children’s cancers are very different than adult cancers and must be treated with specific pediatric cancer protocols. A majority of our protocols come from the Children’s Oncology Group (COG), a national organization funded by the National Cancer Institute (NCI). Our relationship with the COG makes us the only medical center in the region offering Phase 1 COG clinical trials for pediatric cancer patients. Learn about our clinical trials.